Loading...
MonarcHER: A randomized phase II study of abemaciclib plus trastuzumab with or without fulvestrant versus trastuzumab plus standard-of-care chemotherapy in women with HR+, HER2+advanced breast cancer (ABC)
Tolaney, SM Zambelli, S Hilton, J Troso-Sandoval, T Ricci, F Im, SA Kim, SB Johnston, SRD Chan, A
Tolaney, SM
Zambelli, S
Hilton, J
Troso-Sandoval, T
Ricci, F
Im, SA
Kim, SB
Johnston, SRD
Chan, A
Citations
Altmetric:
Abstract
Description
Date
2019
Publisher
Collections
Files
Keywords
Type
Meetings and Proceedings
Citation
Tolaney SM, Wardley AM, Zambelli S, Hilton J, Troso-Sandoval T, Ricci F, et al. LBA23MonarcHER: A randomized phase II study of abemaciclib plus trastuzumab with or without fulvestrant versus trastuzumab plus standard-of-care chemotherapy in women with HR+, HER2+ advanced breast cancer (ABC). Annals of Oncology. 2019;30(Supplement_5):861.